These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Active transport of O-diazoacetyl-L-serine and 6-diazo-5-oxo-L-norleucine in Ehrlich ascites carcinoma. JACQUEZ JA Cancer Res; 1957 Oct; 17(9):890-6. PubMed ID: 13472680 [No Abstract] [Full Text] [Related]
24. The effect of azaserine against Plasmodium lophurae in chicks and attempts to antagonize this effect with metabolites. MCCARTHY DA; BAYLES A; THOMPSON PE J Parasitol; 1957 Jun; 43(3):283-90. PubMed ID: 13439465 [No Abstract] [Full Text] [Related]
25. The development and biochemical characterization of resistance to azaserine in a TA 3 ascites carcinoma. SARTORELLI AC; LePAGE GA Cancer Res; 1958 May; 18(4):457-63. PubMed ID: 13536997 [No Abstract] [Full Text] [Related]
26. Resistance in L1210 ascites without change in concentrative uptake of o-diazoacetyl-L-serine or 6-diazo-5-oxo-L-norleucine. JACQUEZ JA; HUTCHISON DJ Cancer Res; 1959 May; 19(4):397-401. PubMed ID: 13652124 [No Abstract] [Full Text] [Related]
27. The effect of cancer inhibitor drugs on the take of Walker carcinosarcoma 256 in rats. MCDONALD GO; CRUZ EP; COLE WH Surg Forum; 1957; 7():486-9. PubMed ID: 13433422 [No Abstract] [Full Text] [Related]
28. Cytosine-containing hybrid dipeptides: N-[2-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)propionyl]-L-phenylalanine N-[2-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)propionyl]-L-serine monohydrate and N-[2-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)propionyl]-L-lysine. Doi M; Nakamoto Y; Asano A Acta Crystallogr C; 2005 Oct; 61(Pt 10):m577-82. PubMed ID: 16210762 [TBL] [Abstract][Full Text] [Related]
29. [Isolation of Pseudomonas aurantiaca strains capable of overproduction of phenazine antibiotics]. Feklistova IN; Maksimova NP Mikrobiologiia; 2008; 77(2):207-12. PubMed ID: 18522322 [TBL] [Abstract][Full Text] [Related]
31. Study of the interaction between actin and antitumor substance aplyronine A with a novel fluorescent photoaffinity probe. Kuroda T; Suenaga K; Sakakura A; Handa T; Okamoto K; Kigoshi H Bioconjug Chem; 2006; 17(2):524-9. PubMed ID: 16536486 [TBL] [Abstract][Full Text] [Related]
32. Studies on OPSPA. IV. Metabolism of OPSPA in the rat and human. MALLER RK; HEIDELBERGER C Cancer Res; 1957 May; 17(4):296-301. PubMed ID: 13427010 [No Abstract] [Full Text] [Related]
33. REVERSAL OF AZASERINE BY PHENYLALANINE. Brock TD; Brock ML J Bacteriol; 1961 Feb; 81(2):212-7. PubMed ID: 16561885 [No Abstract] [Full Text] [Related]
34. Purine metabolism in bacteria. IV. L-azaserine as an inhibitor. GOLLUB EG; GOTS JS J Bacteriol; 1956 Dec; 72(6):858-64. PubMed ID: 13398378 [No Abstract] [Full Text] [Related]
35. Effects of combinations of azaserine and of 6-diazo-5-oxo-L-norleucine with purine analogs and other antimetabolites on the growth of two mouse mammary carcinomas. TARNOWSKI GS; STOCK CC Cancer Res; 1957 Nov; 17(10):1033-9. PubMed ID: 13489704 [No Abstract] [Full Text] [Related]
37. Observations on the action of azaserine in mammalian tissues. HENDERSON JF; LEPAGE GA; MCIVER FA Cancer Res; 1957 Jul; 17(6):609-12. PubMed ID: 13446847 [No Abstract] [Full Text] [Related]
38. Chromatographic studies of purine metabolism. IV. Reversal of azaserine-induced inhibition by phenylalanine and tryptophan. TOMISEK AJ; REID MR; SKIPPER HE Cancer Res; 1959 Jun; 19(5):489-93. PubMed ID: 13663035 [No Abstract] [Full Text] [Related]